Logotype for Harrow Inc

Harrow (HROW) investor relations material

Harrow Investor Day 2025 summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Harrow Inc
Investor Day 2025 summary26 Sep, 2025

Strategic Vision and Business Model

  • Aims to become the leading U.S. ophthalmic company, leveraging a founder-led, entrepreneurial approach and disciplined M&A to build the largest, most diversified ophthalmic portfolio in North America.

  • Focuses on acquiring and integrating assets that fit strategic, financial, and operational criteria, with a preference for late-stage or commercial products that scale efficiently.

  • Maintains a disciplined capital structure, recently refinancing $250M in unsecured notes, reducing annual interest expense by $3M, and securing additional liquidity through revolving credit facilities.

  • Operates with a target of under 3x gross leverage and under 2x net leverage, with annual revenue growth exceeding 40% (except 2021) over the past five years.

  • Commercial teams are organized by therapeutic area, with programs ensuring patient access for as low as $0 or a maximum of $59, and a scalable platform supporting branded, generic, and compounded products.

Product Portfolio and Pipeline

  • Portfolio spans dry eye, retina, surgical, rare, and specialty ophthalmic products, with leading brands like VEVYE, IHEEZO, TRIESENCE, and upcoming launches including BYQLOVI, BioViz/BYOOVIZ, Opuviz, and Melt 300.

  • VEVYE is the first and only water-free cyclosporine for dry eye, achieving 7.8% US market share in Q2 2025 and strong market share gains, supported by the VAFA access program.

  • Retina franchise is expanding with biosimilars BioViz/BYOOVIZ (Lucentis) and Opuviz (Eylea), both with interchangeability status and expected US launches in 2026 and 2027.

  • Surgical portfolio focuses on perioperative solutions, with TRIESENCE as the only FDA-approved preservative-free injectable steroid, BICLOVI launching in 2026, and Melt 300 (non-IV, non-opioid sedation) expected to file NDA in 2027 and launch in 2028.

  • Pipeline includes a prefilled syringe version of TRIESENCE (targeting 2028), a novel conjunctival delivery device for ocular cancer (potential launch 2029), and ongoing label expansion for Melt 300.

Financial Guidance and Growth Outlook

  • 2025 revenue guidance is over $280M, with a medium-term goal of $250M+ in quarterly revenue by Q4 2027, driven by VEVYE, retina biosimilars, and surgical launches.

  • Gross margins expected in the low to mid-80% range, with operating margins of 30–40% at target revenue levels.

  • Access for All programs (VAFA, HAFA) are designed to maximize patient access, drive prescription volume, and ensure nearly every script is profitable, supporting sustainable revenue growth.

  • Commercial execution is supported by a best-in-class sales team, strategic account initiatives, and a focus on expanding depth and breadth in key segments.

  • M&A remains opportunistic, with a focus on structured deals that fit existing commercial infrastructure and deliver long-term value.

Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.

Next Harrow earnings date

Logotype for Harrow Inc
Q3 202513 Nov, 2025
Your earnings 
season toolkit.
Download
Free on both iOS & Android.

Next Harrow earnings date

Logotype for Harrow Inc
Q3 202513 Nov, 2025

The essential earnings season companion

The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

Live calls and transcripts

Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.

Find what you need faster

Search for any keyword across all transcripts simultaneously.

Easily store key findings

Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Your watchlist. Your dashboard.

Follow the companies that matter to you. Get a personalized feed with real-time updates.

Be the first to know

Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.

Consensus estimates

Access analyst consensus estimates, valuation multiples, and revenue segments splits.

All IR material in one place

The easiest way to stay updated during earnings season.

Global coverage

All events from public companies. Live and recorded.

Just click and listen

No webcast links. No manual registrations.

Research anytime, anywhere

Built for professionals. Loved by everyone. Try our free mobile app.

excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
App-store-avatar.png play-store-avatar.png
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
play-store-avatar
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
App-store-avatar.png play-store-avatar.png
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
x-avatar
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
App-store-avatar.png play-store-avatar.png
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
x-avatar
@theshortbearx.com

Frequently asked questions

Harrow Health Inc is a pharmaceutical company focused on the development and commercialization of ophthalmic pharmaceutical products. The company offers compounded medications and branded formulations for use in eye care. It serves physicians, clinics, and surgical centers in the United States. The company is headquartered in Nashville, Tennessee, and its shares are listed on the NASDAQ.

Quartr provides global coverage of all investor relation material from public companies.

  • Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.

  • Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.

  • Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.

Yes, the Quartr mobile app is free on both iOS and Android.

Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.

Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.

Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.

Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.

Explore our global coverage